Logo image
Back
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario
Journal article   Open access   Peer reviewed

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario

Sharon E Frey, Patricia L Winokur, Robert A Salata, Samer S El-Kamary, Christine B Turley, Emmanuel B Walter, Christine Mhorag Hay, Frances K Newman, Heather R Hill, Ying Zhang, …
Vaccine, Vol.31(29), pp.3025-3033
06/24/2013
DOI: 10.1016/j.vaccine.2013.04.050
PMCID: PMC3755481
PMID: 23664987
url
https://doi.org/10.1016/j.vaccine.2013.04.050View
Published (Version of record) Open Access

Abstract

•Reintroduction of Variola major as an agent of bioterrorism remains a concern.•A compressed schedule of MVA was evaluated for use in a post event scenario.•MVA is well tolerated when given as two standard doses at Days 0 and 28 or 0 and 7.•A 2nd dose of MVA at Day 28 compared to Day 7 provided greater antibody responses.•INF-γ expression was greatest within 2 weeks after last vaccination. Reintroduction of Variola major as an agent of bioterrorism remains a concern. A shortened dosing schedule of Bavarian Nordic's (BN) IMVAMUNE® (modified vaccinia Ankara vaccine against smallpox) was compared to the currently recommended 0- and 28-day schedule for non-inferiority by evaluating the magnitude and kinetics of the immune responses. Subjects were assigned to receive IMVAMUNE or placebo administered subcutaneously on Days 0 and 7, Days 0 and 28, or Day 0. Blood was collected for antibody and cell-mediated immune assays. Subjects were followed for safety for 12 months after last vaccination. The primary endpoint of this study was the geometric mean antibody titers (GMT) at 14 days post last vaccination. Of 208 subjects enrolled, 191 received vaccine (Group: 0+7, Group: 0+28 and Group: 0) and 17 received placebo. Moderate/severe systemic reactogenicity after any vaccination were reported by 31.1%, 25.4%, and 28.6% of the subjects for Group: 0+7, Group: 0+28, and Group: 0, respectively (Chi-square test, P=0.77). Based on BN's Plaque Reduction Assay GMTs, Group: 0+7 was non-inferior to Group: 0+28 at Day 4, 180, and 365 after the second vaccination. On Day 14, Group: 0+7 and Group: 0+28 GMT were 10.8 (CI: 9.0, 12.9) and 30.2 (CI: 22.1, 41.1), respectively. Based on BN's Enzyme-linked immunosorbent assay, the proportion of subjects with positive titers for Group: 0+28 was significantly greater than that for Group: 0+7 after second vaccination at Days 4 and 180. By Day 14 after the second dose, the IFN-γ enzyme-linked immunosorbent spot (ELISPOT) responses were similar for Group: 0+28 and Group: 0+7. Overall, a standard dose of IMVAMUNE (0.5mL of 1x108TCID/mL) administered subcutaneously was safe and well tolerated. A second dose of IMVAMUNE at Day 28 compared to Day 7 provided greater antibody responses and the maximal number of responders. By Day 14 after the second dose, IFN-γ ELISPOT responses were similar for Group: 0+28 and Group: 0+7.
 IMVAMUNE Smallpox MVA Vaccine Bioterrorism Post-event

Details

Metrics

35 Record Views
57 Times Cited - Web of Science
Logo image